ArticleCancer chemotherapy and pharmacology2022
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
Jing Xu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
12 papers cite it
this papercites it